Escient Pharmaceuticals Stock

escientpharma.comHealthcareFounded: 2015Funding to Date: $243.51MM

Escient Pharmaceuticals is a biotech company specializing in the treatment of neurosensory-inflammatory disorders. Escient’s therapeutic programs apply state-of-the-art chemistries and biological understanding for its highly differentiated treatments using a novel class of cellular receptors called Mass-related G protein-coupled receptors (MRGPRS) that can detect and target a broad range of neuro-diseases.

Register for Details

For more details on financing and valuation for Escient Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Escient Pharmaceuticals.

Register Today

Escient Pharmaceuticals investors also invested in these private companies

Team

Management Team

Joshua Grass
Chief Executive Officer
Christian Weyer, MD, MAS
President and Chief Medical Officer
Marcus F. Boehm, PHD
Chief Scientific Officer
Aaron Mishel
Chief Financial Officer

Board Members

Kathleen Sereda Glaub
Chair
Ben Auspitz
Independent Director
Jason P Hafler, PHD
Independent Director
Matt Mcaviney
Independent Director
Jason Punwani
Abingworth
Kevin Raidy
Cowen Healthcare Investments
Andy Schwab
5AM Ventures
Peter Svennilson
The Column Group

Other companies like Escient Pharmaceuticals in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

Startup biotech manages to raise venture capital despite a slowdown in funding amid economic uncertainty